Dan Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dan Gao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Agnes B. Fogo
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
1 shared publication Dongwei Liu
Department of Integrated Traditional and Western Nephrology , the First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan Province , China
1 shared publication- Haichun Yang
Vanderbilt University Medical Center 37232 Nashville TN USA
1 shared publication - Jianyong Zhong
Department of Pediatrics and
1 shared publication - Li-Jun Ma
CVMR-PH Discovery, Johnson & Johnson Innovative Medicine Research & Development, Spring House, Pennsylvania, United States
1 shared publication - Liping Du
Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA
1 shared publication
Latest Publications
- Open Access
- 27 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 6018
Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker
We previously found that short-term treatment (week 8 to 12 after injury) with high-dose angiotensin receptor blocker (ARB) induced the regression of existing glomerulosclerosis in 5/6 nephrectomy rats. We therefore assessed the effects of long-term intervention with ARB vs. nonspecific antihypertensives in this study. Adult rats underwent 5/6 nephrectomy and renal biopsy 8 weeks later. The rats were then divided into three groups with equivalent renal function and glomerular sclerosis and treated with high-dose losartan (ARB), nonspecific antihypertensive triple-therapy (TRX), or left untreated (Control) until week 30. We found that blood pressure, serum creatinine levels, and glomerulosclerosis were lower at sacrifice in ARB and TRX vs. Control. Only ARB reduced proteinuria and maintained the density of WT-1-positive podocytes. Glomerular tufts showed more double-positive cells for CD44, a marker of activated parietal epithelial cells, and synaptopodin after ARB vs. TRX or Control. ARB treatment reduced aldosterone levels. ARB-treated rats had significantly improved survival when compared with TRX or Control. We conclude that both long-term ARB and triple-therapy ameliorate progression, but do not sustain the regression of glomerulosclerosis. ARB resulted in the superior preservation of podocyte integrity and decreased proteinuria and aldosterone, linked to increased survival in the uremic environment.
- 27 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 6018
Open AccessPodocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker
We previously found that short-term treatment (week 8 to 12 after injury) with high-dose angiotensin receptor blocker (ARB) induced the regression of existing glomerulosclerosis in 5/6 nephrectomy rats. We therefore assessed the effects of long-term intervention with ARB vs. nonspecific antihypertensives in this study. Adult rats underwent 5/6 nephrectomy and renal biopsy 8 weeks later. The rats were then divided into three groups with equivalent renal function and glomerular sclerosis and treated with high-dose losartan (ARB), nonspecific antihypertensive triple-therapy (TRX), or left untreated (Control) until week 30. We found that blood pressure, serum creatinine levels, and glomerulosclerosis were lower at sacrifice in ARB and TRX vs. Control. Only ARB reduced proteinuria and maintained the density of WT-1-positive podocytes. Glomerular tufts showed more double-positive cells for CD44, a marker of activated parietal epithelial cells, and synaptopodin after ARB vs. TRX or Control. ARB treatment reduced aldosterone levels. ARB-treated rats had significantly improved survival when compared with TRX or Control. We conclude that both long-term ARB and triple-therapy ameliorate progression, but do not sustain the regression of glomerulosclerosis. ARB resulted in the superior preservation of podocyte integrity and decreased proteinuria and aldosterone, linked to increased survival in the uremic environment.
- Open Access
- 1 September 2021
- Published by Walter de Gruyter GmbH in Diabetic Nephropathy
- Vol. 1 (2) , 90-92
Diabetic nephropathy patient with heavy proteinuria: A case report
We herein report a case of advanced stage rapidly progressive diabetic nephropathy that finally received long-term renal replacement therapy. A 53-year-old man with hypertension and heavy proteinuria suffered rapid progression of DKD [estimated glomerular filtration rate (eGFR): 18 mL/min/1.73m2; proteinuria: 12.21 g/d]. Renal biopsy revealed diabetic nephropathy (Class III) with severe interstitial lesion and tubular atrophy. Despite aggressive treatment, the proteinuria and blood pressure were poorly controlled. The patient finally became dialysis dependent. We hold the position that this is related to his proteinuria and hypertension.
- 1 September 2021
- Published by Walter de Gruyter GmbH in Diabetic Nephropathy
- Vol. 1 (2) , 90-92
Open AccessDiabetic nephropathy patient with heavy proteinuria: A case report
We herein report a case of advanced stage rapidly progressive diabetic nephropathy that finally received long-term renal replacement therapy. A 53-year-old man with hypertension and heavy proteinuria suffered rapid progression of DKD [estimated glomerular filtration rate (eGFR): 18 mL/min/1.73m2; proteinuria: 12.21 g/d]. Renal biopsy revealed diabetic nephropathy (Class III) with severe interstitial lesion and tubular atrophy. Despite aggressive treatment, the proteinuria and blood pressure were poorly controlled. The patient finally became dialysis dependent. We hold the position that this is related to his proteinuria and hypertension.